Explore Hongqi pharmaceutical
More than 30 years of unremitting efforts
Anti tuberculosis drugs
Hongqi pharmaceutical "no longer bothered by tuberculosis"
We should enrich first-line anti tuberculosis drugs, build second-line multi drug resistant anti tuberculosis drugs, and make efforts to benefit global TB patients based on domestic and global perspectives.
In 2019, R & D investment accounts for 7.65% of the company's sales revenue.
Hongqi pharmaceutical has successively introduced rifampicin freeze-dried powder injection for injection and isoniazid injection, and developed a domestic class I new drug PA-824, bringing more drug choices for tuberculosis patients.
Hongqi pharmaceutical builds a new tuberculosis drug production line according to who PQ standard
We have built a professional team for the promotion and service of anti tuberculosis drugs in China, strengthened hospital promotion and channel coverage, and improved academic promotion ability and brand building.
The sky is high and the sea is wide
In 2010, Hongqi pharmaceutical became a member of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical", stock code: 600196. Sh, 02196. HK). With the mission of "no longer suffering from tuberculosis" and the vision of "creating an international first-class anti tuberculosis drug pharmaceutical enterprise", Hongqi Pharmaceutical Co., Ltd. enriches first-line anti tuberculosis drugs, constructs second-line multi drug resistant anti tuberculosis drugs, and is committed to benefiting global TB patients based on domestic and global perspectives.